Lineage Cell Therapeutics, Inc. Announces Resignation of Edward D. Wirth as Chief Medical Officer, Effective from December 15, 2019
October 18, 2019 at 05:02 pm EDT
Share
On October 17, 2019, Edward D. Wirth, III, M.D., Ph.D., who joined Lineage Cell Therapeutics, Inc. as Chief Medical Officer in March 2019 as a result of the company’s acquisition of Asterias Biotherapeutics, Inc., informed the company that he has decided to resign effective December 15, 2019. Dr. Wirth’s resignation is not due to any disagreement with the company on any matter relating to its operations, policies, or practices. Dr. Wirth intends to pursue a career opportunity with a company in a non-competitive area of cell therapy.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
LINEAGE CELL THERAPEUTICS, INC. 
